Velpanat
Sofosbuvir and velpatasvir tablets for chronic hepatitis C. The two antivirals together stop the virus from multiplying.
- Category
- Antivirals
- Active ingredients
- Sofosbuvir · Velpatasvir
- Route
- Oral use
- Form
- Tablet
- Strengths
- 400mg + 100mg
Supply requirements for Velpanat depend on the medicine and destination. The fulfilment partner must confirm them before accepting an order.
Velpanat details
- Condition
- Chronic Hepatitis C
- Alternative names
- Epclusa
- Therapeutic class
- Antiviral
- Pharmacological class
- HCV NS5B inhibitor; HCV NS5A inhibitor
- Contraindications
- hypersensitivity to active substances
- Precautions and warnings
- monitor hepatic function
- Minor side effects
- headache; fatigue; nausea
- Moderate side effects
- insomnia; rash
- Serious side effects
- bradycardia, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Natco Pharma
- Onset Time
- not applicable
- Duration
- 24 hours
- Storage instructions
- Store below 30°C.
- Drug interactions
- Amiodarone; Proton pump inhibitors; St. John's Wort
- Age restrictions
- For adult use.
Patient summary
Sofosbuvir and velpatasvir tablets for chronic hepatitis C. The two antivirals together stop the virus from multiplying.
Mechanism of action
Velpanat combines a nucleotide polymerase inhibitor (sofosbuvir) and a replication complex inhibitor (velpatasvir) to block hepatitis C virus replication, effectively targeting the viral life cycle.
Pregnancy and breastfeeding
Pregnancy: Not recommended unless necessary provided by specialist. Breastfeeding: Consult specialist.